Advanced Filters
noise

atrial-fibrillation Clinical Trials

A listing of atrial-fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 463 clinical trials
P Pavel Osmancik, MD, PhD

Pulsed-field Ablation Vs. Sham Ablation to Treat AF

The study is planned as a single-blind, multicenter, prospective, randomized study. Sixty sbjects will be randomized 1:1 to either: (i) EP study + PFA, or (ii) EP study + Sham ablation control. After informed consent is obtained, an implantable loop recorder (ILR) will be implanted within seven days, and an …

18 years of age All Phase 3
S Stavros Stavrakis, MD, PhD

Synaptic Plasticity in the Epicardial Ganglionated Plexi

Atrial fibrillation (AF) is the most common arrhythmia and the prevalence increase with age. Autonomic nervous system play a critical role in the initiation and maintenance of AF. The intrinsic cardiac autonomic nervous system includes ganglionated plexus (GP) modulate the level of parasympathetic activity to the heart. Experimental and clinical …

21 - 90 years of age All Phase 1
T Tammy Knight

QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT)

Atrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The main …

18 years of age All Phase N/A
M Marcin Demkow, MD PhD

Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients

SAFE-LAAC CKD Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device in patients with the end-stage renal disease treated with chronic haemodialysis or peritoneal dialysis

18 years of age All Phase 4

Safety and Performance of a Pulsed Field Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation

The purpose of this study is to provide clinical data pertaining to the safety and performance of the Globe Mapping and Pulsed Field Ablation System for treating subjects with atrial fibrillation (AF).

18 - 75 years of age All Phase N/A
B Betsy Ellsworth, MSN, ANP

CardioFocus HeartLight Post-Approval Study

This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.

18 years of age All Phase N/A
S Saverio Iacopino, MD

Prospective Evaluation of Biophysical Parameters as Long-term Predictors of Pulmonary Vein Isolation

Current, worldwide assessments of the prevalence of AF estimate that 33 million people are affected by this cardiac arrhythmia. As the most common sustained atrial arrhythmia, AF has a well-established association with systemic embolic events, stroke, heart failure, and increased mortality. Current treatment guidelines and consensus statements for patients with …

18 years of age All Phase N/A
T Tamaz Shaburishvili, MD

Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device

The study is designed to evaluate the safety and performance of the ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients with non-valvular Atrial Fibrillation, who are at increased risk for stroke, and that cannot take, or have a reason to seek an alternative, to long-term anticoagulation therapy. Potential …

18 years of age All Phase N/A
J Jonathan Steinberg

Renal Denervation + PVI vs PVI Alone for Persistent AF

Pulmonary vein isolation (PVI) is the cornerstone of ablation for atrial fibrillation (AF). Increased cardiac sympathetic stimulation can facilitate AF and reduction can be accomplished by renal artery denervation (RDN). The recently completed randomized trial, ERADICATE-AF, convincingly demonstrated that RDN plus PVI resulted in a reduction in recurrent incident AF …

18 years of age All Phase N/A
M Marcin Demkow, MD PhD

Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

SAFE-LAAC Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device

18 years of age All Phase 4

Simplify language using AI